<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04848441</url>
  </required_header>
  <id_info>
    <org_study_id>VACC-COV-19</org_study_id>
    <nct_id>NCT04848441</nct_id>
  </id_info>
  <brief_title>Risk of COVID-19 Infection After Vaccination</brief_title>
  <official_title>Risk of COVID-19 Infection After Vaccination: A Nationwide Study Comparing BNT162b2, mRNA-1273 and ChAdOx1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational nationwide study is to evaluate the effects of three&#xD;
      different COVID-19 vaccines for the outcome of different severities of incident COVID&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incident COVID-19 infection</measure>
    <time_frame>Up to six months after vaccination</time_frame>
    <description>Four different severities: Being diagnosed, hospitalized, ICU-care and death within 30 days of diagnosis</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000000</enrollment>
  <condition>Vaccination; Infection</condition>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1</intervention_name>
    <description>The purpose of the study is to compare the effects of BNT162b2, mRNA-1273 and ChAdOx1 with respect to incident COVID-19 infection of different severities.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will contain all Swedish citizens vaccinated with BNT162b2, mRNA-1273&#xD;
        or ChAdOx1, all Swedish citizens diagnosed with COVID-19, and a control group matched 1:1&#xD;
        on birth year, sex and municipality to the first two groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Living in Sweden and vaccinated with BNT162b2, mRNA-1273 or ChAdOx1&#xD;
&#xD;
          -  All individuals with a previous COVID-19 infection&#xD;
&#xD;
          -  Controls matched 1:1 to the groups above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Nordström, Prof</last_name>
    <phone>+46907851000</phone>
    <email>peter.nordstrom@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcel Ballin, PhD</last_name>
    <email>marcel.ballin@umu.se</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Nationwide observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

